Phathom Pharmaceuticals, INC 10-Q quarterly reports

Phathom Pharmaceuticals announced strong revenue growth in its Q2 2026 report, driven by its VOQUEZNA product line, while managing operating expenses.

Phathom Pharmaceuticals reports a significant increase in Q1 2026 revenue driven by VOQUEZNA sales, while net loss narrows compared to the prior year period.

Phathom Pharmaceuticals reports significant revenue growth and a reduced net loss in Q3 2025, driven by strong VOQUEZNA sales, while managing liquidity and strategic restructuring.

Phathom Pharmaceuticals reported significant product revenue growth for Q2 2025, driven by its VOQUEZNA franchise, while also implementing a workforce reduction to optimize commercial execution.

Phathom Pharmaceuticals reports a net loss of $94.3 million for Q1 2025 and announces a restructuring plan to reduce cash burn and focus on commercial execution.

Phathom Pharmaceuticals reported its Q3 2024 results, highlighting revenue growth from the commercial launch of Voquezna products and ongoing clinical development efforts.

Phathom Pharmaceuticals reports a net loss of $91.4 million for the second quarter of 2024, with product revenue of $7.3 million following the launch of Voquezna.

Phathom Pharmaceuticals has filed an amended 10-Q report to correct an inadvertent omission of language in the certifications of its CEO and CFO.

Phathom Pharmaceuticals reports a net loss of $82.9 million for the first quarter of 2024, with initial product revenue of $1.9 million following the launch of Voquezna.